Marc Wein is an Endocrinology/Metabolic physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Massachusetts General Hospital
55 Fruit St.
Boston, MA 02114
Telephone
617-726-2862Registry record last updated 28 Mar 2014.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Alexion Pharmaceuticals, Inc.Program year20254 payments
- BioMarin Pharmaceutical Inc.Program year20251 payment
- AstraZeneca UK LimitedProgram year20222 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Hormonal (systemic)
73.4%Parathyroid Hormone-Related Peptide Analog25.8%Tymlos100%Part D<11 patientsParathyroid Hormone Analog25%Teriparatide100%Part D<11 patients+ 1 more class in this area
Genitourinary & hormones
26.6%Estrogen Agonist/Antagonist13.3%Raloxifene Hcl100%Part D<11 patientsAndrogen13.3%Testosterone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
6 NIH research awards on record, funded 2013–2026 per NIH RePORTER. The latest:
- Center of Research Translation on Osteoporosis Bone Anabolic Therapies
Massachusetts General Hospital
FY2026$1,363,916P50AR080596 - The role of salt inducible kinases in parathyroid hormone action in bone
Massachusetts General Hospital
FY2026$442,486R01DK116716
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”